SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-20-000103
Filing Date
2020-11-09
Accepted
2020-11-09 16:10:02
Documents
17
Period of Report
2020-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20201109.htm   iXBRL 8-K 42809
2 EX-99.1 rvncq320exhibit991.htm EX-99.1 146743
3 EX-99.2 rvncq320exhibit992.htm EX-99.2 19080
9 newrevancelogo1.jpg GRAPHIC 11936
  Complete submission text file 0001479290-20-000103.txt   387871

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20201109.xsd EX-101.SCH 2458
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20201109_cal.xml EX-101.CAL 744
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20201109_def.xml EX-101.DEF 1689
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20201109_lab.xml EX-101.LAB 24275
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20201109_pre.xml EX-101.PRE 12680
10 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20201109_htm.xml XML 11310
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 201297762
SIC: 2834 Pharmaceutical Preparations